+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06557733

Evaluating TPST-1495 for Safety and Effectiveness in Reducing Polyps in Familial Adenomatous Polyposis

Led by National Cancer Institute (NCI) · Updated on 2026-09-14

38

Participants Needed

4

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the drug TPST-1495 in patients with familial adenomatous polyposis FAP, an inherited condition that causes numerous polyps to form in the colon and rectum, increasing the risk of colon cancer. This open-label phase II trial aims to assess how well TPST-1495 reduces polyp burden in the small bowel and colon, as well as its safety in patients with FAP. Participants take TPST-1495 orally once daily for six months, unless unacceptable side effects occur. They undergo esophagogastroduodenoscopy EGD and gastrointestinal endoscopy with biopsies at the start and end of treatment. Blood samples are collected throughout the study to monitor biological changes. After completing treatment, participants have a follow-up visit one month later. During the trial, researchers evaluate changes in duodenal and rectalpouch polyp burden from baseline to six months and monitor adverse events up to seven months. They also analyze tissue samples for markers like COX-2 expression and proteomic profiles from serum samples. Safety is closely observed through clinical assessments and laboratory tests, with the total study participation lasting about seven months.

CONDITIONS

Brief Title

An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here